Just published by "Science Daily" and featured on Google finance about Insmed. Yahoo won't let me post a link. Go to Google to find article. Very promising.
"June 25, 2013 — Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model. The findings, published in Human Molecular Genetics, represent a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases..."
Your guess is as good as mine. However, will Insmed have to say anything at this time? It doesn't appear to be an Insmed study. Right now their priority is Arikace. But, I'm still excited by iPlex.
"remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. "
Sentiment: Strong Buy
Here is more from the Oxford Journals:
Triggering Regeneration and Tackling Apoptosis: A Combinatorial Approach to Treating MDC1A
Received April 5, 2013.
Revision received June 7, 2013.
Accepted June 11, 2013
"To accomplish this task we generated Bax-null Lama2Dy-wmice that overexpressed muscle specific IGF-1 (Lama2Dy-wBax−/-+IGF-1tg). Further to test the translational potential of IGF-1 administration in combination with Bax inhibition, we treated Lama2Dy-wBax−/-mice postnatally with systemic recombinant human IGF-1 (IPLEXTM). These two combinatorial treatments lead to similar, promising outcomes.
In addition to increased body and muscle weights, both transgenic overexpression and systemic administration of IGF-1 combined with Bax-inhibition resulted in improved muscle phenotype and locomotory function that were nearly indistinguishable from wild type mice. These results provide a fundamental proof-of-concept that justifies the use of a combination therapy as an effective treatment for MDC1A, and highlights a compelling argument towards shifting the paradigm in treating multifaceted neuromuscular diseases."
"shifting the paradigm in treating multifaceted neuromuscular diseases."
but insmed has stopped the manufacturing of iplex long ago. do they still own the patent?
July 27, 2009
Insmed Provides Update on Supply of IPLEX(TM)
--Company to Provide Remaining Supply of IPLEX(TM) to Ensure Continued Access
RICHMOND, Va., July 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that, effective immediately, the Company will cease the supply of IPLEX((TM)) to any new patients. In addition, the Company will not initiate further clinical trials with IPLEX((TM)) at this time. The Company has determined that its limited inventory on hand must be conserved for the treatment of existing patients.
Following the previously announced sale of Insmed's Boulder, Colorado manufacturing facility to Merck & Co., Inc. in March 2009, Insmed no longer has the capability to manufacture IPLEX((TM)), an extremely complicated drug to produce. Moreover, any agreement with a third party to undertake the manufacture of IPLEX((TM)), if it was economically feasible and could be arranged, would not result in production of additional quantities of IPLEX(TM) for at least 12 to 18 months.
There are approximately 70 patients who currently receive IPLEX(TM), 12 in the U.S. and the remainder around the rest of the world. Most of the patients receive IPLEX(TM) pursuant to a court-ordered Extended Access . The Company believes that it has sufficient IPLEX(TM) inventory to supply these patients for no more than 24 months.
The Company intends to analyze the on-going data collected for various indications, including myotonic muscular dystrophy and ALS, and assess the overall IPLEX(TM) development program, including possible IPLEX(TM) manufacturing options with third parties and possible future clinical trials. Initiation of the Phase II clinical trial for ALS patients in the U.S. that had been discussed with FDA earlier this year has been postponed while the Company performs this assessment.
The article was just published today by Science Daily (a very reputable entity) and clearly spells out that research was conducted with "IPLEX TM, manufactured by Insmed Inc." It seems there have been certain activities regarding the manufacturing of IPLEX that has not been made public yet. I recall Will Lewis was answering a question during the quarterly financial results and said Insmed is in discussions with an entity regarding IPLEX, but would not elaborate further. The good news is published results are great to Insmed and Muscular Dystrophy patients.
Why no PR from Insmed yet?
An excerpt from the article:
"The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc)."
More excerpt,. Note their words: "remarkable improvement in in muscle pathology..."
"By combining these two therapies [one of which is IPLEX], researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
Research highlighted in this news release was funded in part by Cure CMD, Struggle against Muscular Dystrophy (S.A.M), and the Muscular Dystrophy Association (MDA)."